Niacinamide (Vitamin B3) Supports general well-being and contributes to normal energy metabolism
Digestive effects such as nausea, vomiting, diarrhea, constipation, appetite changes, and abdominal discomfort are commonly discussed with incretin-based therapies
Currently: Victoza is approved for children with Type 2 diabetes as young as ten years old Both Saxenda and Wegovy are approved for children 12 years and older The FDA is currently considering approving liraglutide for children as young as six years old The Canadian Medical Association Journal (CMAJ) has also advised using GLP-1 drugs and surgery, when appropriate, representing a growing international consensus on these treatments
With the exception of mean heart rate (HR) which decreased in the L-Carnitine-combination group, and mean diastolic blood pressure which increased in the L-Carnitine group, there were no significant differences in systolic blood pressure, weight, or BMI between interventions